Should Invesco S&P SmallCap Quality ETF (XSHQ) Be on Your Investing Radar?
Overview of Invesco S&P SmallCap Quality ETF (XSHQ): Launched in 2017, XSHQ is a passively managed ETF focusing on small-cap blend stocks, with assets over $332 million and an expense ratio of 0.29%. It aims to match the performance of the SmallCap 600 Quality Index, primarily investing in the Financials sector.
Performance and Investment Considerations: The ETF has shown an 8.40% increase this year and 23.26% over the past year, with a Zacks ETF Rank of 3 (Hold). Investors are encouraged to consider other similar ETFs like iShares Russell 2000 and iShares Core S&P Small-Cap for diversified options.
Trade with 70% Backtested Accuracy
Analyst Views on IWM
About the author
U.S. Stocks Turn Negative as Nasdaq Falls 0.57% and S&P 500 Declines 0.17% Amid Rising Oil Prices and Geopolitical Concerns.
Market Performance: U.S. stocks experienced a reversal in intraday trading, with the Nasdaq down 0.57% and the S&P 500 off 0.17%.
Influencing Factors: The decline in stock prices was influenced by rising oil prices and increasing geopolitical tensions, which weighed on market sentiment.
Russell 2000 Stocks: Is It Premature or Time to Pay Attention?
Small-Cap Stocks Overview: Many top mega-cap companies began as speculative small-cap stocks, but the best stocks are those that consistently grow revenue and earnings, despite the higher volatility associated with small-cap stocks.
Market Conditions and Interest Rates: The cost of capital has increased due to higher interest rates, impacting small-cap companies that often rely on debt for growth, contrasting with previous low-interest environments.
Russell 2000 Index Performance: The Russell 2000 index, representing small-cap stocks, has seen a slight decline this year, but it has maintained solid performance over the past three years, with a significant valuation gap compared to the S&P 500.
Investment Opportunities in Small-Cap Stocks: Analysts suggest that now may be a good time to invest in Russell 2000 stocks, especially as market conditions hint at potential lower interest rates, which could attract investor interest in these stocks.
TNXP Shares Plummet for Four Consecutive Days as Investors Anticipate Drug Pipeline Returns
Tonix Pharmaceuticals Updates: Tonix is evaluating its Tonmya drug for treating major depressive disorder and acute stress disorder, with plans to initiate a U.S. field study in 2027 for its experimental drug TNX-4800 aimed at seasonal prevention of Lyme disease.
Stock Performance: Shares of Tonix Pharmaceuticals (TNXP) have fallen for four consecutive days, although retail sentiment around the stock has increased by 92% in the past 24 hours, with analysts rating it a 'Buy'.
Drug Approvals and Usage: The U.S. FDA approved Tonix's Tonmya for managing fibromyalgia in adults, and over 2,500 patients have started treatment with it since its launch in November.
Future Pipeline Candidates: Tonix's pipeline includes TNX-2900 for treating Prader-Willi syndrome, TNX-1500 for preventing kidney transplant rejection, and TNX-1900 for treating migraines, with analysts suggesting a potential upside for the stock.
RCKT Shares Plummet Following Gene Therapy Approval as Wall Street Overlooks Decline
FDA Approval: Rocket Pharmaceuticals received FDA approval for its gene therapy Kresladi, aimed at treating a rare inherited pediatric disorder, marking a significant milestone for the company.
Stock Market Reaction: Following the announcement, Rocket Pharmaceuticals' stock dropped by 22%, reflecting investor concerns despite the positive FDA news.
Analyst Insights: Analysts from LifeSci Capital reiterated an 'Outperform' rating for Rocket Pharmaceuticals, suggesting that the FDA's Rare Pediatric Disease Priority Review Voucher could enhance the company's financial position significantly.
Market Sentiment: Retail sentiment around Rocket's stock remained bullish, although the stock has seen a 53% decline over the past year, indicating mixed investor confidence.
KODK Stock Surpasses $10 for the First Time in Almost 5 Years — Retail Investors Celebrate 'Kodak Moment'
Retail Sentiment Surge: Retail chatter on Stocktwits increased by 25%, indicating a shift from 'normal' to 'high' levels of engagement, particularly around Eastman Kodak's recent performance.
Eastman Kodak's Financial Results: The company reported Q4 2025 earnings with revenues of $290 million, reflecting a 9% growth, and operational earnings before interest, tax, depreciation, and amortization (EBITDA) increased by 144%.
Stock Price Milestone: Kodak's shares surged over 12% on Friday, briefly surpassing the $10 mark for the first time since June 2021, garnering significant attention from retail traders.
Improved Financial Position: Kodak reduced its annual interest expense by approximately $40 million, resulting in a stronger balance sheet, with a cash balance of $337 million as of December 31, 2025, and more cash than debt for the first time in years.
BUR Stock Plummets 37% After US Appeals Court Ruling — What's the Link to Argentina?
Argentina's Nationalization of YPF: In 2012, Argentina nationalized 51% of YPF, its largest oil company, which led to Repsol losing control and an agreement to pay $5 billion in compensation in 2014.
Lawsuit and Award: In 2023, a lawsuit backed by Burford Capital was filed by YPF's minority shareholders, claiming harm from the nationalization, resulting in a $16.1 billion award against Argentina.
Court Ruling Impact: A U.S. federal appeals court overturned a previous ruling that favored YPF's former shareholders, stating the prior judge had ruled incorrectly.
Market Reaction: Following the court ruling, Burford Capital's shares dropped significantly, reflecting investor concerns about the implications of the legal decisions on the company's future.
U.S. Stocks Turn Negative as Nasdaq Falls 0.57% and S&P 500 Declines 0.17% Amid Rising Oil Prices and Geopolitical Concerns.
Market Performance: U.S. stocks experienced a reversal in intraday trading, with the Nasdaq down 0.57% and the S&P 500 off 0.17%.
Influencing Factors: The decline in stock prices was influenced by rising oil prices and increasing geopolitical tensions, which weighed on market sentiment.
Russell 2000 Stocks: Is It Premature or Time to Pay Attention?
Small-Cap Stocks Overview: Many top mega-cap companies began as speculative small-cap stocks, but the best stocks are those that consistently grow revenue and earnings, despite the higher volatility associated with small-cap stocks.
Market Conditions and Interest Rates: The cost of capital has increased due to higher interest rates, impacting small-cap companies that often rely on debt for growth, contrasting with previous low-interest environments.
Russell 2000 Index Performance: The Russell 2000 index, representing small-cap stocks, has seen a slight decline this year, but it has maintained solid performance over the past three years, with a significant valuation gap compared to the S&P 500.
Investment Opportunities in Small-Cap Stocks: Analysts suggest that now may be a good time to invest in Russell 2000 stocks, especially as market conditions hint at potential lower interest rates, which could attract investor interest in these stocks.
TNXP Shares Plummet for Four Consecutive Days as Investors Anticipate Drug Pipeline Returns
Tonix Pharmaceuticals Updates: Tonix is evaluating its Tonmya drug for treating major depressive disorder and acute stress disorder, with plans to initiate a U.S. field study in 2027 for its experimental drug TNX-4800 aimed at seasonal prevention of Lyme disease.
Stock Performance: Shares of Tonix Pharmaceuticals (TNXP) have fallen for four consecutive days, although retail sentiment around the stock has increased by 92% in the past 24 hours, with analysts rating it a 'Buy'.
Drug Approvals and Usage: The U.S. FDA approved Tonix's Tonmya for managing fibromyalgia in adults, and over 2,500 patients have started treatment with it since its launch in November.
Future Pipeline Candidates: Tonix's pipeline includes TNX-2900 for treating Prader-Willi syndrome, TNX-1500 for preventing kidney transplant rejection, and TNX-1900 for treating migraines, with analysts suggesting a potential upside for the stock.
RCKT Shares Plummet Following Gene Therapy Approval as Wall Street Overlooks Decline
FDA Approval: Rocket Pharmaceuticals received FDA approval for its gene therapy Kresladi, aimed at treating a rare inherited pediatric disorder, marking a significant milestone for the company.
Stock Market Reaction: Following the announcement, Rocket Pharmaceuticals' stock dropped by 22%, reflecting investor concerns despite the positive FDA news.
Analyst Insights: Analysts from LifeSci Capital reiterated an 'Outperform' rating for Rocket Pharmaceuticals, suggesting that the FDA's Rare Pediatric Disease Priority Review Voucher could enhance the company's financial position significantly.
Market Sentiment: Retail sentiment around Rocket's stock remained bullish, although the stock has seen a 53% decline over the past year, indicating mixed investor confidence.
KODK Stock Surpasses $10 for the First Time in Almost 5 Years — Retail Investors Celebrate 'Kodak Moment'
Retail Sentiment Surge: Retail chatter on Stocktwits increased by 25%, indicating a shift from 'normal' to 'high' levels of engagement, particularly around Eastman Kodak's recent performance.
Eastman Kodak's Financial Results: The company reported Q4 2025 earnings with revenues of $290 million, reflecting a 9% growth, and operational earnings before interest, tax, depreciation, and amortization (EBITDA) increased by 144%.
Stock Price Milestone: Kodak's shares surged over 12% on Friday, briefly surpassing the $10 mark for the first time since June 2021, garnering significant attention from retail traders.
Improved Financial Position: Kodak reduced its annual interest expense by approximately $40 million, resulting in a stronger balance sheet, with a cash balance of $337 million as of December 31, 2025, and more cash than debt for the first time in years.
BUR Stock Plummets 37% After US Appeals Court Ruling — What's the Link to Argentina?
Argentina's Nationalization of YPF: In 2012, Argentina nationalized 51% of YPF, its largest oil company, which led to Repsol losing control and an agreement to pay $5 billion in compensation in 2014.
Lawsuit and Award: In 2023, a lawsuit backed by Burford Capital was filed by YPF's minority shareholders, claiming harm from the nationalization, resulting in a $16.1 billion award against Argentina.
Court Ruling Impact: A U.S. federal appeals court overturned a previous ruling that favored YPF's former shareholders, stating the prior judge had ruled incorrectly.
Market Reaction: Following the court ruling, Burford Capital's shares dropped significantly, reflecting investor concerns about the implications of the legal decisions on the company's future.
